Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CFO Oluyemi Okupe sold 7,950 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $23.64, for a total transaction of $187,938.00. Following the completion of the transaction, the chief financial officer directly owned 262,954 shares of the company’s stock, valued at $6,216,232.56. This trade represents a 2.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oluyemi Okupe also recently made the following trade(s):
- On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.96, for a total value of $588,564.20.
- On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.90, for a total value of $956,279.80.
- On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.83, for a total value of $501,079.15.
- On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.98, for a total value of $79,420.50.
- On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.77, for a total value of $219,088.09.
Hims & Hers Health Trading Up 4.1%
Shares of NYSE HIMS opened at $23.98 on Friday. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $70.43. The business has a fifty day moving average price of $24.08 and a 200 day moving average price of $28.13. The stock has a market capitalization of $5.47 billion, a P/E ratio of -266.43, a price-to-earnings-growth ratio of 21.68 and a beta of 2.43. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56.
Key Stories Impacting Hims & Hers Health
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: Hims & Hers expanded its GLP-1 offering in Canada by launching access to generic semaglutide, its first international generic GLP-1 product. The move could help broaden the company’s customer base and strengthen its growth story outside the U.S. Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
- Positive Sentiment: The Canadian semaglutide launch reinforces Hims & Hers’ broader international expansion strategy and ability to offer lower-cost GLP-1 treatments in a market where affordability has been a barrier. Hims & Hers launches generics for Novo’s semaglutide in Canada
- Neutral Sentiment: Analysts continue to debate the stock’s setup after the earnings miss, with some noting the long-term GLP-1 opportunity still intact even as near-term sentiment remains cautious. The Silver Lining of Last Week’s Hims and Hers Earnings Miss
- Negative Sentiment: Investor concern about dilution from the company’s recent convertible note offering has weighed on the stock, offsetting some of the optimism around new capital and expansion plans. Hims & Hers stock slips as dilution fears outweigh new capital
- Negative Sentiment: Sentiment remains hurt by the recent Q1 earnings miss and softer-than-expected revenue, which reminded investors that execution risk is still high despite the company’s strategic pivot in weight-loss offerings. 5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings Call
Institutional Investors Weigh In On Hims & Hers Health
A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE lifted its position in Hims & Hers Health by 194.4% during the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after acquiring an additional 2,877,550 shares during the period. Farallon Capital Management LLC increased its holdings in shares of Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. Norges Bank purchased a new position in shares of Hims & Hers Health in the fourth quarter worth about $62,153,000. Invesco Ltd. raised its stake in shares of Hims & Hers Health by 62.7% in the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after purchasing an additional 1,600,004 shares during the last quarter. Finally, Clear Street Group Inc. acquired a new stake in shares of Hims & Hers Health during the third quarter worth about $87,372,000. 63.52% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
HIMS has been the subject of a number of analyst reports. Morgan Stanley decreased their target price on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. Evercore set a $24.00 price target on Hims & Hers Health in a research report on Tuesday, February 24th. Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a report on Tuesday, May 12th. BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Finally, Canaccord Genuity Group set a $32.00 target price on Hims & Hers Health in a research note on Tuesday, May 12th. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $29.37.
View Our Latest Report on HIMS
About Hims & Hers Health
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Articles
- Five stocks we like better than Hims & Hers Health
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
